Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation

Journal of Clinical Investigation

Volumn 126, Issue 4, 2016, Pages 1337-1352

  Nguyen, Hung D ^a   Chatterjee, Shilpak ^a   Haarberg, Kelley M K ^b   Wu, Yongxia ^a   Bastian, David ^a   Heinrichs, Jessica ^a,c   Fu, Jianing ^a,d   Daenthanasanmak, Anusara ^a   Schutt, Steven ^a   Shrestha, Sharad ^e   Liu, Chen ^f   Wang, Honglin ^g   Chi, Hongbo ^e   Mehrotra, Shikhar ^a   Yu, Xue Zhong ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; ALLOANTIGEN; FATTY ACID; FRUCTOSE 2,6 BIPHOSPHATASE 3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATASE; PYRUVIC ACID; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PFKFB3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DONOR; FATTY ACID OXIDATION; GLYCOLYSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OXIDATION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; T LYMPHOCYTE; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CITRIC ACID CYCLE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; PATHOLOGY;

ALLOGRAFTS; ANIMALS; CITRIC ACID CYCLE; GLYCOLYSIS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PHOSPHOFRUCTOKINASE-2; TOR SERINE-THREONINE KINASES;

EID: 84964600705     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82587     Document Type: Article

References (67)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.
2. Wahl DR, Petersen B, Warner R, Richardson BC, Glick GD, Opipari AW. Characterization of the metabolic phenotype of chronically activated lymphocytes. Lupus. 2010;19(13):1492-1501.
3. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J Exp Med. 2013;210(10):2119-2134.
4. Biniecka M, et al. Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis. Arthritis Rheum. 2011;63(8):2172-2182.
5. Gerriets VA, et al. Metabolic programming PDHK1 control CD4+ T cell subsets inflammation. J Clin Invest. 2015;125(1):194-207.
6. Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. Trends Immunol. 2012;33(4):168-173.
7. Lee CF, et al. Preventing allograft rejection by targeting immune metabolism. Cell Rep. 2015;13(4):760-770.
8. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity. 2007;27(2):173-178.
9. Wang R, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871-882.
10. Macintyre AN, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014;20(1):61-72.
11. Byersdorfer CA, et al. Effector T cells require fatty acid metabolism during murine graft-versushost disease. Blood. 2013;122(18):3230-3237.
12. Gatza E, et al. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med. 2011;3(67):67ra8.
13. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342(6155):1242454.
14. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012;12(5):325-338.
15. Delgoffe GM, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30(6):832-844.
16. Yang K, et al. T cell exit from quiescence and differentiation into Th2 cells depend on RaptormTORC1-mediated metabolic reprogramming. Immunity. 2013;39(6):1043-1056.
17. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013;499(7459):485-490.
18. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(pt 20):3589-3594.
19. Delgoffe GM, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011;12(4):295-303.
20. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009;8(7):1026-1029.
21. Marti HP, Frey FJ. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant. 2005;20(1):13-15.
22. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med. 2005;201(2):259-266.
23. Frauwirth KA, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769-777.
24. Chang CH, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239-1251.
25. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63(14):3847-3854.
26. Filosa S, et al. Failure to increase glucose consumption through the pentose-phosphate pathway results in the death of glucose-6-phosphate dehydrogenase gene-deleted mouse embryonic stem cells subjected to oxidative stress. Biochem J. 2003;370(pt 3):935-943.
27. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev. 2012;249(1):43-58.
28. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease-and graft-versusleukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 1998;160(11):5355-5365.
29. Lee K, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity. 2010;32(6):743-753.
30. Crome SQ, Wang AY, Kang CY, Levings MK. The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells. Eur J Immunol. 2009;39(6):1480-1493.
31. Sackstein R. A revision of Billingham's tenets: The central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12(1 suppl 1):2-8.
32. Shi LZ, et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367-1376.
33. van der Waart AB, van der Velden WJ, Blijlevens NM, Dolstra H. Targeting the IL17 pathway for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(6):752-759.
34. Clem BF, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 2013;12(8):1461-1470.
35. Schoors S, et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014;19(1):37-48.
36. Van Schaftingen E, Hue L, Hers HG. Fructose 2,6-bisphosphate, the probably structure of the glucose-and glucagon-sensitive stimulator of phosphofructokinase. Biochem J. 1980;192(3):897-901.
37. Berod L, et al. De novo fatty acid synthesis controls the fate between regulatory T T helper 17 cells. Nat Med. 2014;20(11):1327-1333.
38. O'Sullivan D, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity. 2014;41(1):75-88.
39. Glick GD, et al. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther. 2014;351(2):298-307.
40. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518(7539):413-416.
41. van der Windt GJ, et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci U S A. 2013;110(35):14336-14341.
42. Duvel K, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171-183.
43. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39-68.
44. Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD. Anergic T cells are metabolically anergic. J Immunol. 2009;183(10):6095-6101.
45. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
46. Jacobs SR, Michalek RD, Rathmell JC. IL-7 is essential for homeostatic control of T cell metabolism in vivo. J Immunol. 2010;184(7):3461-3469.
47. Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005;174(8):4670-4677.
48. Haas R, et al. Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol. 2015;13(7):e1002202.
49. Komanduri KV, Champlin RE. Can Treg therapy prevent GVHD? Blood. 2011;117(3):751-752.
50. Sukumar M, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest. 2013;123(10):4479-4488.
51. Lu SX, et al. Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease. J Immunol. 2010;185(3):1912-1919.
52. Finlay DK, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209(13):2441-2453.
53. Pulsipher MA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: A phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014;123(13):2017-2025.
54. Pulsipher MA, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol. 2009;147(5):691-699.
55. Yalcin A, et al. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem. 2009;284(36):24223-24232.
56. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, Hue L. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-tohead with a bifunctional enzyme that controls glycolysis. Biochem J. 2004;381(pt 3):561-579.
57. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol. 2009;86(3):174-179.
58. Telang S, et al. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. J Transl Med. 2012;10:95.
59. Haarberg KM, et al. Pharmacologic inhibition of PKCα and PKCtheta prevents GVHD while preserving GVL activity in mice. Blood. 2013;122(14):2500-2511.
60. Liang Y, et al. β2 Integrins separate graft-versushost disease and graft-versus-leukemia effects. Blood. 2008;111(2):954-962.
61. Capasso M, et al. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol. 2010;11(3):265-272.
62. Everts B, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood. 2012;120(7):1422-1431.
63. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: A resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010;38(Database issue):D792-D799.
64. Chan O, Burke JD, Gao DF, Fish EN. The chemo kine CCL5 regulates glucose uptake and AMP kinase signaling in activated T cells to facilitate chemotaxis. J Biol Chem. 2012;287(35):29406-29416.
65. Iclozan C, et al. T helper17 cells are sufficient but not necessary to induce acute graft-versushost disease. Biol Blood Marrow Transplant. 2010;16(2):170-178.
66. Yu XZ, Liang Y, Nurieva RI, Guo F, Anasetti C, Dong C. Opposing effects of ICOS on graftversus-host disease mediated by CD4 and CD8 T cells. J Immunol. 2006;176(12):7394-7401.
67. Gruber T, et al. PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo. Mol Immunol. 2009;46(10):2071-2079.